Total parathyroidectomy with forearm autotransplantation as the treatment of choice for secondary hyperparathyroidism

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 978-987

  Naranda, J ^a,b   Ekart, R ^a,b   Pecovnik Balon B ^a,b  

^a UNIVERSITY OF MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Bone mineral density; Calcification; Chronic kidney disease; Hyperparathyroidism; Mineral and bone disease; Mineral metabolism; Parathyroidectomy

Indexed keywords

ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; BONE DENSITY; BONE DISEASE; BONE PAIN; BONE TRANSPLANTATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; FEMALE; FOREARM AUTOTRANSPLANTATION; FRACTURE; HEMODIALYSIS PATIENT; HUMAN; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE PERIOD; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM;

EID: 80052244020     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900333     Document Type: Article

References (45)

1. Moe S, Drüeke T, Cunningham J, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
2. Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771-789.
3. Hernández A, Concepción MT, Rodríguez M, et al: High phosphorus diet increases preproPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int 1996; 50: 1872-1878.
4. Nichols P, Owen JP, Ellis HA, et al: Parathyroidectomy in chronic renal failure: a nine-year follow-up study. Q J Med 1990; 77: 1175-1193.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kid Int 2009; 76(suppl 113): S1-S130.
6. Guérin AP, London GM, Marchais SJ, et al: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2001; 15: 1014-1021.
7. Safar ME, Blacher J, Pannier B, et al: Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-738.
8. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354.
9. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11(suppl 3): 130-135.
10. Martin KJ, González EA: Metabolic bone disease and chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885.
11. Neyer U, Hoerandner H, Haid A, et al: Total parathyroidectomy with autotransplantation in renal hyperparathyroidism: low recurrence after intra-operative tissue selection. Nephrol Dial Transplant 2002; 17: 625-629.
12. Coladonato JA: Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005; 16(suppl 2): S107-S114.
13. Quarles LD, Davidai GA, Schwab SJ, et al: Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: 840-844.
14. Mundy GR, Guise TA: Hormonal control of calcium homeostasis. Clin Chem 1999; 45: 1347-1352.
15. Shevde NK, Plum LA, Clagett-Dame M, et al: A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A 2002; 99: 13487-13491.
16. Goodman WG: Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18(suppl 3): iii2-iii8.
17. Malluche HH, Mawad H: Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant 2002; 17: 1170-1175.
18. Drueke T, Martin D, Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007; 22: 1828-1839.
19. Lewin E, Huan J, Olgaard K: Parathyroid growth and suppression in renal failure. Semin Dial 2006; 19: 238-245.
20. Berkoben M, Cronin RE, Quarles LD: Indications for parathyroidectomy in end-stage renal disease. UpToDate (available at: http://www.uptodate.com/contents/indicationsfor-parathyroidectomy-in-end-stage-renaldisease? source=search_result&selectedTitle=1% 7E150).
21. Ritter CS, Martin DR, Lu Y, et al: Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 2002; 17: 2206-2213.
22. Quarles LD, Davidai GA, Schwab SJ, et al: Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: 840-844.
23. Fabretti F, Calabrese V, Fornasari V, et al: Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol 1991; 105: 562-567.
24. Llach F: Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int Suppl 1990; 29: S62-S68.
25. Abdelhadi M, Nordenström J: Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 3845-3851.
26. Taal MW, Masud T, Green D, et al: Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922-1928.
27. Agatston AS, Janowitz WR, Hildner FJ, et al: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
28. Malberti F, Farina M, Imbasciati E: The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999; 14: 2398-2406.
29. Rudser KD, de Boer IH, Dooley A, et al: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407.
30. Bover J, Rodriguez M, Trinidad P, et al: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 1994; 45: 953-961.
31. Cozzolino M, Brandenburg V: Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the U. Clin Nephrol 2009; 71: 593-601.
32. Goodman WG, Frazao JM, Goodkin DA, et al: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-445.
33. Goodman WG: Recent developments in the management of secondary hyperpara-thyroidism. Kidney Int 2001; 59: 1187-1201.
34. Chen RA, Goodman WG: Role of the calciumsensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004; 286: F1005-F1011.
35. Block GA, Hulbert-Shearon TE, Levin NW, et al: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
36. Kaye M, Rosenthall L, Hill RO, et al: Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993; 39: 192-197.
37. Rashed A, Fahmi M, ElSayed M, et al: Effectiveness of surgical parathyroidectomy for secondary hyperparathyroidism in renal dialysis patients in Qatar. Transplant Proc 2004; 36: 1815-1817.
38. Gagné ER, Ureña P, Leite-Silva S, et al: Shortand long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1008-1017.
39. Kestenbaum B, Andress DL, Schwartz SM, et al: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016.
40. Mazzaferro S, Pasquali M, Farcomeni A, et al: Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 2008; 23: 2319-2323.
41. Torres A, Lorenzo V, Hernández D, et al: Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
42. Qi Q, Monier-Faugere MC, Geng Z, et al: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
43. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 suppl 3): S1-S201.
44. Coen G, Calabria S, Bellinghieri G, et al: Parathyroidectomy in chronic renal failure: short-and long-term results on parathyroid function, blood pressure and anemia. Nephron 2001; 88: 149-155.
45. Sato S, Ohta M, Kawaguchi Y, et al: Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 67-71.